Passage BIO, Inc. (PASG): R&D Expense
$23.28M
Year ended 2025-12-31
$17.16M
Trailing 12 months to 2026-06-30
-35.3%
3-year compound annual growth
-22.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $23.28M | -42.1% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $40.18M | -34.6% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $61.42M | -28.6% | 2025-03-04, From 2023-01-01 |
| 2022-12-31 | $86.05M | -26.9% | 2024-03-04, From 2022-01-01 |
| 2021-12-31 | $117.67M | +43.9% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $81.79M | +175.0% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $29.74M | n/a | 2021-03-03, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Passage BIO, Inc. (PASG) | 2025-12-31 | $23.28M | -42.1% |
| Elutia Inc. (ELUT) | 2025-12-31 | $4.16M | +38.9% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $35.33M | -4.1% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $112.67M | +1.0% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $250.0K | -18.6% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $37.59M | +9.4% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $23.72M | -31.1% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $1.87M | -52.4% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $37.19M | -10.8% |
Compare PASG, ELUT, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗